Hikma Pharmaceutical | HIK - Selling And Administration Expenses


Hikma Pharmaceutical reported $288M in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Almirall -29.5M 4.72M Jun/2026
argenx SE USD 598M 181M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Autolus Therapeutics Ltd USD 39.95M 4.16M Mar/2026
Bayer EUR 4.02B 53M Sep/2026
Fresenius EUR 823M 63M Sep/2026
Genmab DKK 205M 39M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
GRIFOLS EUR 326M 37M Sep/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.58B 11M Sep/2026
Orion EUR 98.9M 0 Sep/2026
Recordati EUR 189.59M 12M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
UCB EUR 1.47B 193M Dec/2025